Sorafenib High quality with Factory price CAS NO.284461-73-0

Min.Order: 10 Milligram
Payment Terms: T/T
Available Specifications:

Product Details

Keywords

Sorafenib
284461-73-0
standard supplier in China

Quick Details

ProName: Sorafenib
CasNo: 284461-73-0
Molecular Formula: C21H16ClF3N4O3
Appearance: detailed see specifications
Application: analysis,activity test,Botanical Refer...
DeliveryTime: 1-3?working?days?after?confirming?the?...
PackAge: According to the clients requirement.
Port: China main port
ProductionCapacity: 1 Metric Ton/Day
Purity: ≥98%
Storage: Store at 2~8°C
Transportation: by air or by ocean shipping
LimitNum: 10 Milligram
Plant of Origin: Chinese herbal medicine
Testing Method: NMR/MS/HPLC
Product Ecification: 1mg-1kg
Heavy Metal: <10ppm
Voluntary Standards: company standard
Storage: Brown vial HDPE plastic bottle

Superiority

Hubei CuiRan Biotechnology Co., Ltd is a leading company in the research, development, manufacture and marketing of High Quality Phytochemicals and Extracts(especially Active Ingredients from Traditional Chinese Medicine，Traditional Chinese Medicine), Natural Active Pharmaceutical Ingredients worldwide. From small quantities for R&D or reference standard, to large quantities for customizing or manufacturing, Biopurify emphasizes on consistent and reliable services for his customers.
With excellent quality products and good service, we have clients from more than dozens countries and regions, and we pride ourselves in providing our customers with a total satisfaction experiences.
We are doing our best to be your reliable partner for high quality Phytochemicals and Reference Standards from china.

Our main services:
A. Supply active ingredients and reference standards ofTraditional Chinese Medicine, from mgs to kgs scale.
B. Custom extraction and purification, target Herb Active Ingredients
C. Custom synthesis and semi-synthesis for Natural Active Ingredients
D. CR, CM and PD services from lab scale, pilot scale to commercial scale(GMP is also available)
E.Traditional Chinese Medicine compounds library

1.Provide traditional Chinese medicine reference materials and natural active ingredients;
2.More than 2200 compounds are available for selection, continuously building high-quality natural product libraries for drug research and development;
3.Provide various screening libraries and more inhibitor products;
4.Provide separation and structural determination of natural products;
5.Laboratory scale pilot to commercial scale collaborative research and process development services.More than 180 experiences in phytochemistry (still increasing)
Each product has passed very strict testing (NMR/MS/HPLC)
Agents from many countries

General tips：For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging：1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition：Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Details

Chemical Properties of Sorafenib

Cas No.	284461-73-0	SDF
PubChem ID	216239	Appearance	Powder
Formula	C₂₁H₁₆ClF₃N₄O₃	M.Wt	464.83
Type of Compound	Alkaloids	Storage	Desiccate at -20°C
Synonyms	Bay 43-9006
Solubility	DMSO : ≥ 45 mg/mL (96.81 mM) *"≥" means soluble, but saturation unknown.
Chemical Name	4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
SMILES	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Standard InChIKey	MLDQJTXFUGDVEO-UHFFFAOYSA-N
Standard InChI	InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging	1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment.
Shipping Condition	Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Sorafenib

Description	Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.Sorafenib together with inhibitors of the β-catenin pathway might be an effective tool in the treatment of pediatric HCC. The combination of Sorafenib with AMPK activators could have beneficial effects on tumor regression by AMPK pathway activation. The combination of metformin or other AMPK activators and Sorafenib could be tested in prospective clinical trials.
Targets	AMPK \| Wnt/β-catenin \| mTOR \| ERK \| VEGFR-3 \| B-Raf \| Raf-1
In vitro	MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.[Pubmed: 25712526] Biochem Biophys Res Commun. 2015 Apr 3;459(2):234-9. Chemotherapy-induced autophagy activation often contributes to cancer resistance. MiRNA-30a (miR-30a) is a potent inhibitor of autophagy by downregulating Beclin-1. In this study, we characterized the role of miR-30a in Sorafenib-induced activity in renal cell carcinoma (RCC) cells. METHODS AND RESULTS: We found that expression of miR-30a was significantly downregulated in several human RCC tissues and in RCC cell lines. Accordingly, its targeted gene Beclin-1 was upregulated. Sorafenib activated autophagy in RCC cells (786-0 and A489 lines), evidenced by p62 degradation, Beclin-1/autophagy protein 5 (ATG-5) upregulation and light chain (LC)3B-I/-II conversion. Exogenously expressing miR-30a in 786-0 or A489 cells inhibited Beclin-1 expression and enhanced Sorafenib-induced cytotoxicity. In contrast, knockdown of miR-30a by introducing antagomiR-30a increased Beclin-1 expression, and inhibited Sorafenib-induced cytotoxicity against RCC cells. Autophagy inhibitors, including chloroquine, 3-methyaldenine or Bafliomycin A1, enhanced Sorafenib activity, causing substantial cell apoptosis. Meanwhile, knockdown of Beclin-1 or ATG-5 by targeted siRNAs also increased Sorafenib-induced cytotoxicity in above RCC cells. CONCLUSIONS: These findings indicate that dysregulation of miR-30a in RCC may interfere with the effectiveness of Sorafenib-mediated apoptosis by an autophagy-dependent pathway, thus representing a novel potential therapeutic target for RCC.
In vivo	Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.[Pubmed: 25646358] Jpn J Clin Oncol. 2015 Apr;45(4):336-42. Sorafenib is a recommended treatment for advanced hepatocellular carcinoma. The study is to evaluate the efficacy of Sorafenib plus cyproheptadine compared with Sorafenib alone in patients with advanced hepatocellular carcinoma. METHODS AND RESULTS: A retrospective cohort study reviewed all consecutive advanced hepatocellular carcinoma cases with Child-Pugh Class A disease starting Sorafenib treatment at our hospital from August 2012 to March 2013. They were followed up until 31 December 2013. A total of 52 patients were enrolled: 32 patients in the combination (Sorafenib-cyproheptadine) group and 20 patients in the control (Sorafenib alone) group. The response to treatment, overall survival and progression-free survival were compared. The median overall survival was 11.0 months (95% confidence interval: 6.8-15.1 months) in the combination group compared with 4.8 months (95% confidence interval: 3.1-6.6 months) in the control group (crude hazard ratio = 0.45, 95% confidence interval: 0.22-0.82). The median progression-free survival time was 7.5 months (95% confidence interval: 5.1-10.0 months) in the combination group compared with 1.7 months (95% confidence interval: 1.4-2.1 months) in the control group (crude hazard ratio = 0.43, 95% confidence interval: 0.22-0.86). Kaplan-Meier survival analysis revealed that both overall survival and progression-free survival in the combination group were significantly longer than that in the control group. The multivariate model found patients in the combination group were 76% less likely to die (adjusted hazard ratio = 0.24, 95% confidence interval: 0.10-0.58) and 82% less likely to have progression (adjusted hazard ratio = 0.18, 95% confidence interval: 0.08-0.44) during the 17 months of follow-up. CONCLUSIONS: Cyproheptadine may significantly improve survival outcomes of Sorafenib-treated advanced hepatocellular carcinoma patients. Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.[Pubmed: 25750346] Anticancer Res. 2015 Mar;35(3):1803-8. Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC). Multiple forms of cytotoxicity are induced by Sorafenib in HCC cells in vitro but it is unclear what extent of apoptosis and necrosis is induced in HCC patients receiving Sorafenib. METHODS AND RESULTS: The M30 and M65 biomarkers, which reflect the release of cytokeratin-18 and its apoptotic cleavage fragments, were measured in patients with HCC (n=36) and matched patients with cirrhosis (n=47). A serum sample was collected from 20 patients with HCC four weeks after the onset of treatment with Sorafenib. Basal serum levels of M30 and M65 were increased in patients with HCC compared to those with uncomplicated cirrhosis. No statistically significant increase in the level of M30 or M65 was found in the sera of patients with HCC after Sorafenib. CONCLUSIONS: The findings indicate that Sorafenib is not a potent inducer of HCC cell death in most patients.

Protocol of Sorafenib

Kinase Assay

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.[Pubmed: 25080865]

Int J Cancer. 2015 Mar 15;136(6):1434-44.

The multikinase inhibitor Sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of Sorafenib using combination strategies is a major clinical challenge.
METHODS AND RESULTS:
Here, we identify Sorafenib as an activator of AMP-activated protein kinase (AMPK), in a manner that involves either upstream LKB1 or CAMKK2. We further show in a phase II clinical trial in KRAS mutant advanced non-small cell lung cancer (NSCLC) with single agent Sorafenib an improved disease control rate in patients using the antidiabetic drug metformin. Consistent with this, Sorafenib and metformin act synergistically in inhibiting cellular proliferation in NSCLC in vitro and in vivo. A synergistic effect of both drugs is also seen on phosphorylation of the AMPKα activation site. Our results provide a rationale for the synergistic antiproliferative effects, given that AMPK inhibits downstream mTOR signaling.
CONCLUSIONS:
These data suggest that the combination of Sorafenib with AMPK activators could have beneficial effects on tumor regression by AMPK pathway activation. The combination of metformin or other AMPK activators and Sorafenib could be tested in prospective clinical trials.

Animal Research

Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.[Pubmed: 25447203]

Exp Cell Res. 2015 Feb 1;331(1):97-104.

Treatment outcome of children with pediatric hepatocellular carcinoma (pHCC) is poor. Therefore, we evaluated the tyrosine kinase inhibitor Sorafenib in a model of pHCC.
METHODS AND RESULTS:
Cell viability after treatment with Sorafenib was evaluated in HC-AFW1 cells (pHCC) using MTT assay and compared to an adult HCC (aHCC) and two hepatoblastoma (HB) cell lines. ERK, pERK, E-cadherin, and vimentin expression were investigated using Western Blot. Sorafenib (60 mg/kg) was administered orally to NOD.Cg-Prkdcscid-IL2rgtmWjl/Sz mice bearing subcutaneous HC-AFW1-derived tumors. Tumor progression, viability, and vascularization were monitored by tumor volume, AFP levels, and CD31 immunostaining, respectively. Sensitization to Sorafenib was evaluated using the β-catenin inhibitor ICG001. Sorafenib reduced cell viability in HC-AFW1 (IC50: 8 µM), comparable to HB cells, however less pronounced in aHCC cells (IC50: 23 µM). Sorafenib inhibited ERK signaling in both, HC-AFW1 cells and -xenografts. In vivo, Sorafenib treatment only led to a moderate tumor growth inhibition, although significant reduction of vascularization and tumor growth kinetics was observed. Long-term treatment with Sorafenib decreased E-cadherin, but showed no induction of vimentin expression. Combining Sorafenib with a β-catenin inhibitor led to an additional reduction of cell viability.
CONCLUSIONS:
Sorafenib together with inhibitors of the β-catenin pathway might be an effective tool in the treatment of pediatric HCC.

Preparing Stock Solutions of Sorafenib

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	2.1513 mL	10.7566 mL	21.5132 mL	43.0265 mL	53.7831 mL
5 mM	0.4303 mL	2.1513 mL	4.3026 mL	8.6053 mL	10.7566 mL
10 mM	0.2151 mL	1.0757 mL	2.1513 mL	4.3026 mL	5.3783 mL
50 mM	0.043 mL	0.2151 mL	0.4303 mL	0.8605 mL	1.0757 mL
100 mM	0.0215 mL	0.1076 mL	0.2151 mL	0.4303 mL	0.5378 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.